Authors

Catherine Frenette, MD, FAST, AGAF, Scripps MD Anderson Cancer Center

Catherine Frenette, MD, Scripps Green Hospital

Catherine Lyons, RN, MS

Latest:

Merging Community Practices With an Academic Cancer Center

Consolidation of community oncology practices with hospital-based cancer centers is an accelerating trend that will affect future healthcare delivery models. This year, the Community Oncology Alliance reported hospital acquisitions and corporate mergers among 55% of 1338 community oncology practices surveyed, representing a 20% increase over the previous year's results.

Catherine M. Diefenbach, MD

Latest:

Dr. Diefenbach on Polatuzumab Vedotin Plus Obinutuzumab and Lenalidomide in FL

Catherine M. Diefenbach, MD, discusses polatuzumab vedotin (Polivy) plus obinutuzumab (Gazyva) and lenalidomide (Revlimid) in patients with follicular lymphoma.

Catherine Pietanza, MD

Latest:

Dr. Pietanza on Rova-T for Small Cell Lung Cancer

Catherine Pietanza, MD, assistant attending physician at Memorial Sloan Kettering Cancer Center, discusses novel targeted therapy rovalpituzumab tesirine (Rova-T), which showed activity in relapsed and refractory small cell lung cancer (SCLC) in a recent phase I study.

Catherine Smith, MD

Latest:

Dr. Smith on Acquired Resistance to Targeted Agents for AML

Catherine Smith, MD, assistant professor, Division of Hematology/Oncology, Department of Medicine, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, discusses patient acquired resistance in quizartinib (AC220) and gilteritinib (ASP2215) in acute myeloid leukemia (AML).

Catherine T. Frenette, MD, MD Anderson Cancer Center

Catherine T. Frenette, MD, Scripps Green Hospital

Catherine Tsien Swick

Latest:

More Effort Needed to Understand Value Breadth of Molecular Testing

As the use of testing increases, so does the importance of understanding exactly what it can do for your patients and how to get the most out of the results.

Cathy Bealer, RN, MHA

Latest:

How Does IT Affect Quality of Care?

Oncology practices across the country are using computer technology to improve outcomes and quality of care for our patients.

Cathy Eng, MD

Latest:

Dr. Eng on the Rationale for Studying the Impact of RAS Mutations in Early Onset Resectable CRC

Cathy Eng, MD, FACP, FASCO, discusses the rationale for studying the impact of RAS mutations in patients with early onset resectable colorectal cancer.

Cathy Eng, MD, FACP, FASCO

Latest:

Dr Eng on Unmet Needs Within the mCRC Treatment Paradigm

Cathy Eng, MD, FACP, FASCO, discusses unmet needs within the metastatic colorectal cancer treatment paradigm.

Cathy Eng, MD, FACP, MD Anderson Cancer Center

Cathy Eng, MD, FACP, The University of Texas MD Anderson Cancer Center

Latest:

Second-Line Treatment of mCRC: Rechallenging Therapy

The role of molecular assays, including liquid biopsies, in providing information on resistance mechanisms in metastatic colorectal cancer and the impact of testing results on decisions for rechallenging with a previous therapy.

Cathy Eng, MD, Vanderbilt University

Latest:

Audience Q&A: Best Practices in Managing HER2-Amplified CRC

Fielding questions from the audience, expert oncologists discuss clinical trials, molecular testing, and early-stage disease in the context of HER2-amplified colorectal cancer.

Cecile Pizot

Latest:

Cecile Pizot on Breast Cancer Mortality in Latin America and Asia

Cecile Pizot, biostatistician in epidemiology at the International Prevention Research Institute, discusses the changes in mortality rates in breast cancer around the world. In a study on 47 countries, 39 saw breast cancer mortality rates decline, but mortality rates were on the rise in Latin American and Asian countries.

Cedar Sinai Medical Center

Latest:

Study Shows Gene Expression in Cancerous Bladder Tumors Differs by Race

A new study led by Cedars-Sinai Cancer investigators shows for the first time that gene expression differs by race in patients with high-risk non-muscle-invasive bladder cancer.

Celeste Bello, MD

Latest:

Dr. Bello on Biomarkers in Follicular Lymphoma

Celeste Bello, MD, hematologist/oncologist, Moffitt Cancer Center, discusses investigational biomarkers in follicular lymphoma.

Celeste Lebbe, MD, PhD

Latest:

Dr. Lebbe Discusses Efficacy of Avelumab in Merkel Cell Carcinoma

Celeste Lebbe, MD, PhD, Hopital Saint Louis in Paris, discusses the efficacy of avelumab (Bavencio) in patients with stage IV Merkel cell carcinoma.

Celestia Higano, MD

Latest:

Dr. Higano on the Effectiveness of PARP Inhibitors for Prostate Cancer

Celestia Higano, MD, professor of medicine and urology at the University of Washington, and a member of the Clinical Research Division at Fred Hutchinson Cancer Research Center, discusses the effectiveness of PARP inhibitors for patients with metastatic prostate cancer.